| Literature DB >> 28843322 |
Chekrallah Chamandi1, Rishi Puri1, Tania Rodriguez-Gabella1, Josep Rodés-Cabau2.
Abstract
Transcatheter aortic valve replacement (TAVR) is a well-established treatment for patients with severe symptomatic aortic stenosis who are at high or prohibitive surgical risk. More recently, TAVR has emerged as a valid alternative to surgical aortic valve replacement for treating intermediate-risk patients, and several studies are currently evaluating the role of TAVR in low-risk patients. Transcatheter heart valve (THV) technologies have evolved considerably over time, and important iterations have been implemented in many of the latest-generation devices to (1) reduce the size and improve delivery system properties; (2) improve valve deployment, repositioning, and retrievability; and (3) reduce paravalvular leaks. This article reviews the main characteristics of, and clinical results associated with, the newer-generation THVs while providing an overview of novel TAVR indications.Entities:
Mesh:
Year: 2017 PMID: 28843322 DOI: 10.1016/j.cjca.2017.03.012
Source DB: PubMed Journal: Can J Cardiol ISSN: 0828-282X Impact factor: 5.223